A clinical trial to see the effects of Pathyadi Kwatha and Anu Taila Nasya in Patients with Ardhavabhedaka (Migraine)

Clinical evaluation of Pathyadi Kwatha and Anu Taila Nasya in the management of Ardhavabhedaka (Migraine). - Migraine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020392

Enrollment

120

Registered

2019-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G431- Migraine with aura Health Condition 2: G430- Migraine without aura

Interventions

Intervention1: Pathyadi Kwatha Anu Taila: 1) Pathyadi Kwatha- [Ref.-A.F.I, Part-2, Vol.4:15.] Ingredients- Haritaki, Bibhitaki, Amalaki, Kiratatikta, Haridra, Nimba and Guduchi. Dose : 50 ml. Do

before food. Anupana : Guda Duration of therapy : 84 days (12 weeks) (Add 16 times of potable water in 25 g Kvatha churna and boil till it is reduced to 1/8, filter and consume) 2) Anu Taila

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged in between 18 to 60 years. 2. Diagnosed cases of Migraine with aura /without aura as per as per International Headache Society-ICHD-III (International classification of Headache Disorders 3rd version). 3. Patients with up to Grade III on MIDAS Scale. 4. Frequency of headache is > two times in a month. 5. Willing and able to participate for 3 months (consent to be obtained from patients).

Exclusion criteria

Exclusion criteria: 1. Patients who were suffering with headache due to space occupying lesions and other secondary reasons. 2. Patients with severe infection and/or clinically significant respiratory, cardiac or haematological disorders. 3. Hypertensive patients who are on Î² blockers. 4. Patients with uncontrolled Diabetes mellitus (HbA1C >8%). 5. Patients with uncontrolled Hypothyroidism (S.TSH >10mIU/ml). 6. Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.4 mg/dl) 7. Alcoholics and/or drug abusers. 8. Known cases of malignancy. 9. Pregnant women or planning to conceive or lactating woman. 10. Patients in whom another investigational drug was used within 3 months prior to entry in this study. 11. Any other condition, which the PI thinks, may jeopardize the study.

Design outcomes

Primary

Measure	Time frame
To assess the Clinical Efficacy of Pathyadi Kwatha and Anu Taila Nasya in the management of Ardhavabhedaka (Migraine)Timepoint: 12 WEEKS	—

Secondary

Measure	Time frame
To assess the Clinical Safety of Pathyadi Kwatha and Anu Taila Nasya in patients suffering with Ardhavabhedaka (Migraine)Timepoint: 12 WEEKS	—

Countries

India

Contacts

Public ContactSrinibash Sahoo

Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi

srinibash1970@gmail.com08026995323

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026